Found
6 known investors
Found offers clinically-led, personalized weight care that combines evidence-based medical treatment (including provider-prescribed medications) with support to help members lose weight and improve their health. It serves individuals seeking accessible, judgment-free weight management.
Also known as Found Health, Inc. · joinfound.com
Investors · 6
Company profile
researched Aug 2026Found (Found Health, Inc.) operates an online, clinician-led weight management program. Members complete a 10-15 minute health assessment covering medical history, prior weight loss attempts and daily routine; a board-certified clinician reviews the assessment within roughly one to two days for medical safety and treatment suitability, and, where eligible, prescribes medication that is shipped directly to the member. Care is delivered fully online through secure messaging with no in-office visits, and includes monthly provider check-ins, dose optimization, prescription adjustments and refills, plus nutrition and lifestyle guidance and support navigating insurance coverage.
The medication toolkit spans compounded semaglutide and compounded tirzepatide as well as branded products including Wegovy, Zepbound, Ozempic, Mounjaro, Rybelsus, Saxenda, Trulicity, Victoza, Contrave, Foundayo, metformin, topiramate and zonisamide. Found also markets microdosing options, a GLP-1 coverage checker, and a Medicare GLP-1 Bridge Program that helps eligible Medicare Part D members with a qualifying GLP-1 prescription access brand-name medications for as little as $50 per month, with Found handling insurance paperwork; the company states it is not affiliated with or endorsed by CMS. Adjacent health areas the program associates with weight care include sleep apnea, diabetes, blood pressure, cholesterol, joint and back pain, and mental health.
Beyond the direct-to-consumer program, the company markets channels for businesses and health plans, publishes a blog and resource center, and offers free calculators (BMI, BMR, calorie, protein, waist-to-hip). Members also receive access to a members-only community and to "Aimee," an AI health companion available 24/7.
Business model
Found sells a monthly membership that bundles access to licensed clinicians, personalized care plans, prescription management and ongoing support. Compounded medications are included in the price of both cash-pay and insurance plans, while branded GLP-1 medications are billed separately. Cash-pay members pay a flat monthly price with no copay; insured members pay the plan price plus a copay, which the company says is typically around $30. Memberships are HSA/FSA eligible, plans can be switched at any time, and prepaid annual plans are offered at a discount. Listed medication prices include Ozempic at $1,100 per month and Wegovy from $650 per month.
Recurring subscription fees for membership and clinical care, monthly or prepaid annually, plus medication costs that are either included in the plan (compounded semaglutide and tirzepatide) or billed separately (branded GLP-1s).
Traction
The company reports more than 300,000 members served and 1.4 million pounds lost by members. It cites internal data from 1,773 users who reported weight at least once per week on average for a year showing an average loss of 12% of body weight, and states 83% of members sustain results for one year and that more than 80% of members report no side effects when starting treatment.
Latest developments
Found is marketing a Medicare GLP-1 Bridge Program for eligible Part D members aged 65-75, offering brand-name GLP-1s such as Wegovy, Foundayo and Zepbound for as little as $50 per month, alongside a branded medication, Foundayo, and microdosing options.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
Found positions itself as an affordable, clinician-led alternative in the GLP-1 telehealth weight-care market, emphasizing insurance coverage support, pricing below standard market rates for comparable GLP-1 programs, and clinical protocols designed by obesity medicine specialists.
Points of differentiation the company cites include its MetabolicPrint personalization engine, inclusion of compounded medications in membership pricing, insurance navigation and in-network coverage with top plans, a Medicare Part D bridge program for members aged 65-75, monthly clinician check-ins, and a members-only peer community.
Technology
Care is delivered through a telehealth platform with online assessments, secure messaging and 24/7 access to an AI health companion called Aimee. Found uses a proprietary personalization tool it calls MetabolicPrint, which analyzes biological factors to categorize members into four metabolic profiles and informs clinicians' treatment, dosing and maintenance decisions.
Go-to-market
Direct-to-consumer online acquisition via the company website, with a free insurance coverage check and GLP-1 coverage checker as entry points, promotional discounts (for example up to $100 off checkout or per-month savings on prepaid annual plans), member testimonials, educational content and health calculators. Additional partnership channels target employers and health plans.
US adults seeking medically supervised weight loss, including people eligible for GLP-1 therapy under obesity criteria (BMI ≥30, or ≥27 with a weight-related condition), insured and cash-pay consumers, and Medicare Part D members aged 65-75 via the Medicare GLP-1 Bridge Program. The company also markets to employers ("for business") and health plans.
Geography
United States; services are delivered online nationally, with insurance and Medicare Part D programs specific to the US market.
History
The website is operated by Found Health, Inc., with a 2025 copyright notice.
Risks & controversies
The company's marketing carries extensive disclaimers: GLP-1 medications carry black box warnings, prescriptions are at a provider's discretion, testimonial subjects are paid for appearance and individual results vary, and eligibility for the Medicare bridge program is not guaranteed. Reliance on compounded semaglutide and tirzepatide, insurance coverage dynamics and Medicare copay structures (the $50 copay does not count toward Part D deductible or out-of-pocket maximum, and low-income subsidies do not apply) are relevant operational sensitivities.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 1
launches, deals, and filingsFound began serving members aged 65-75, offering eligible Medicare Part D members with a qualifying GLP-1 prescription access to brand-name GLP-1 medications (Wegovy, Foundayo, Zepbound) for as little as $50 per month, with Found handling insurance paperwork and providing clinician support.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- Foundjoinfound.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Found do?
- Found is a US telehealth weight-care program offering clinician-prescribed GLP-1 medications and ongoing support by subscription.
- Who are Found's investors?
- Found's investors include 1/1 Capital, Able Partners, Atomic, Define Ventures, IVP (Institutional Venture Partners), The Chernin Group (TCG Crypto).